Halia Therapeutics Announces First Healthy Volunteer Dosed with HT-4253, a Novel Oral LRRK2 Inhibitor Targeting Neuroinflammation in Alzheimer’s Disease

October 7, 2024 UCBN News, Syndication Comments Off on Halia Therapeutics Announces First Healthy Volunteer Dosed with HT-4253, a Novel Oral LRRK2 Inhibitor Targeting Neuroinflammation in Alzheimer’s Disease

LEHI, Utah, Oct. 7, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company at the forefront of developing innovative treatments for inflammatory and neurodegenerative diseases, today announced that the first healthy volunteer was dosed in its Phase 1 clinical…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Related Articles

No Picture
News

Awardco Partners with InHealth Strategies to Offer More Robust Health & Wellness Programs

January 24, 2023 UCBN News Comments Off on Awardco Partners with InHealth Strategies to Offer More Robust Health & Wellness Programs

New partnership provides proven, data-driven employee wellness programs with engaging incentives and rewards. LEHI, Utah, Jan. 24, 2023 /PRNewswire/ — Awardco announced today a partnership with inHealth Strategies to encourage health initiatives within organizations and […]

No Picture
News

Portal Innovations Scales with New Science Incubator on its Powered by Portal Platform at Woodbine Labs in Salt Lake City

March 5, 2026 UCBN News, Syndication Comments Off on Portal Innovations Scales with New Science Incubator on its Powered by Portal Platform at Woodbine Labs in Salt Lake City

SALT LAKE CITY–(BUSINESS WIRE)–Portal Innovations continues to rapidly scale Powered by Portal, its managed services platform, with the launch of a new 30,000-square-foot science incubator at Woodbine Labs in Salt Lake City, Utah. Set to […]